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Abstract
Introduction: Transmission through breastfeeding remains important for mother-to-child transmission (MTCT) in resource-
limited settings. We quantify the relationship between cell-free (RNA) and cell-associated (DNA) shedding of HIV-1 virus in
breastmilk and the risk of postnatal HIV-1 transmission in the first 6 months postpartum.
Materials and Methods: Thirty-six HIV-positive mothers who transmitted HIV-1 by breastfeeding were matched to 36 non-
transmitting HIV-1 infected mothers in a case-control study nested in a cohort of HIV-infected women. RNA and DNA were
quantified in the same breastmilk sample taken at 6 weeks and 6 months. Cox regression analysis assessed the association
between cell-free and cell-associated virus levels and risk of postnatal HIV-1 transmission.
Results: There were higher median levels of cell-free than cell-associated HIV-1 virus (per ml) in breastmilk at 6 weeks and 6
months. Multivariably, adjusting for antenatal CD4 count and maternal plasma viral load, at 6 weeks, each 10-fold increase in
cell-free or cell-associated levels (per ml) was significantly associated with HIV-1 transmission but stronger for cell-associated
than cell-free levels [2.47 (95% CI 1.33–4.59) vs. aHR 1.52 (95% CI, 1.17–1.96), respectively]. At 6 months, cell-free and cell-
associated levels (per ml) in breastmilk remained significantly associated with HIV-1 transmission but was stronger for cell-
free than cell-associated levels [aHR 2.53 (95% CI 1.64–3.92) vs. 1.73 (95% CI 0.94–3.19), respectively].
Conclusions: The findings suggest that cell-associated virus level (per ml) is more important for early postpartum HIV-1
transmission (at 6 weeks) than cell-free virus. As cell-associated virus levels have been consistently detected in breastmilk
despite antiretroviral therapy, this highlights a potential challenge for resource-limited settings to achieve the UNAIDS goal
for 2015 of eliminating vertical transmission. More studies would further knowledge on mechanisms of HIV-1 transmission
and help develop more effective drugs during lactation.
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Introduction
Globally, in 2010, an estimated 2.7 million people became
infected with human immunodeficiency virus (HIV); 1.9 million
(70%) of new infections occurred in sub-Saharan Africa (SSA) [1].
An estimated 390,000 (340,000–450,000) new infections occurred
in children, 90% of these in SSA, mainly through mother-to-child
transmission (MTCT) [1]. MTCT can occur before, during and
after delivery, with postnatal transmission through breastfeeding
which accounts for one-third to one-half of MTCT remaining an
unresolved issue [2]. With maternal antiretroviral therapy (ART),
the risk of MTCT can be substantially reduced [3–5]. However,
ART is not always available in resource-limited settings with high
HIV prevalence, where breastfeeding is the norm for infant
survival, and where the provision of ART to the mother or the
infant for up to one year of breastfeeding as per the current WHO
guidelines [6] poses a challenge. Therefore, postnatal transmission
of HIV-1 through breastfeeding is likely to remain an issue for the
foreseeable future in resource-limited settings.
Although factors associated with MTCT have been quantified
[7–10], the mechanisms underlying postnatal transmission remain
poorly understood, in particular the relative roles of cell-free
(RNA) and cell-associated (DNA) HIV-1 in breastmilk trans-
mission. High levels of cell-free virus in maternal plasma and
breastmilk are associated with a high risk of HIV-1 transmission
during breastfeeding [11–16]. Similarly, an association has been
observed with cell-associated virus in breastmilk, suggesting both
cell-free and cell-associated are involved in breastmilk HIV-1
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transmission [11,17,18]. We previously showed that cumulative
exposure to RNA particles in breastmilk significantly increased the
risk of HIV-1 acquisition postnatally independently from maternal
antenatal CD4 cell count, plasma HIV-1 load, child sex and
duration of breastfeeding [19]. Recent studies observe that while
ART leads to undetectable levels of cell-free HIV-1 virus, cell-
associated virus levels are still detected in breastmilk [20,21].
Additionally, there are suggestions that cell-free and cell-associated
virus vary in their prediction of HIV-1 transmission at early and
late lactation stages [18]. If studies confirm such variations in
HIV-1 transmission, and cell-associated virus levels are barely
affected by maternal ART, this could account for the residual
HIV-1 transmission during lactation.
This study examines the prevalence of, and quantifies the
relationship between, cell-free and cell-associated shedding of
HIV-1 virus in breastmilk and the risk of postnatal HIV-1
transmission, in both right and left breasts over the first 6 months
postpartum.
Materials and Methods
Study Population
HIV-infected and HIV-uninfected women were enrolled in an
intervention cohort study, between August 2001 and September
2004 [22,23], to investigate whether breastfeeding in a high HIV
prevalence, poor rural setting in South Africa could be made safe
in terms of both HIV-1 transmission and infant morbidity and
mortality. Weekly home visits documented infant feeding and
morbidity while clinic follow-up of the infants and mothers were
scheduled monthly between 6 weeks and 9 months. Ten milliliters
of breastmilk were collected from each breast for HIV-infected
and uninfected breastfeeding mothers at each scheduled clinic
visit. Samples were transported and maintained at 4 degrees
Celsius overnight and stored long-term as whole breastmilk at
minus 80 degrees Celsius until testing.
A dried blood spot for each infant was collected at each visit and
stored at minus 20 degrees Celsius. HIV-1 RNA quantification
was performed using the Nuclisens HIV-1 QT assay (Organon
Teknika, Boxtel, Netherlands) and Nuclisens EasyQ HIV-1 assay
(Biomerieux, Boxtel, Netherlands) with a sensitivity of 80 copies
HIV-1 RNA per ml of blood (equivalent to 1600 copies HIV-1
RNA per 50 ml dried blood spot) [24]. Rates of MTCT of HIV-1
during breastfeeding have been described previously [23].
Children were considered infected through breastfeeding if they
had a negative HIV polymerase chain reaction (PCR) assay at 6
weeks of age and a positive PCR at any time thereafter. Single-
dose nevirapine (sdNVP) for use during labour/delivery was
provided for all HIV-infected women and to their newborns; ART
for treatment or as MTCT prophylaxis from early in pregnancy or
during the postnatal period was not available in the public health
setting at the time of this study. Maternal viral load and CD4
count were collected antenatally. The project was approved by the
Biomedical Ethics Review Committee (BREC) at the University of
KwaZulu-Natal South Africa.
Study Design
A case-control study was nested in this intervention cohort [22].
The primary study identified 42 babies who had acquired HIV
infection postnatally (as diagnosed by PCR conversion) [23]. Our
study includes 36 postnatally infected children who had both cell-
free and cell-associated data on samples at 6 weeks and 6 months,
and who were matched to controls. Cases and controls were
matched (in a 1:1 ratio) on infant age at breastmilk sampling with
a maximum allowance of 2 weeks of the sample date of the case to
reduce potential bias of varying concentrations of breastmilk RNA
and DNA over time [25]. Cases were mothers who transmitted
HIV-1 to their infants through breastmilk between 6 and 28 weeks
postpartum while controls were non-transmitting HIV-1 infected
mothers. Transmission was estimated to have occurred at the
midpoint between an infant’s last HIV negative PCR test and first
positive result. Infants were included if they had at least one cell-
free and one cell-associated breastmilk sample available close to
the estimated time of transmission (ETT). Breastmilk samples from
both breasts, for postnatal transmitters and controls had DNA
quantified twice (at 6 weeks and 6 months) and RNA at multiple
time points before 6 months. Thirty-six transmitting mothers had
85 samples tested for HIV-1 RNA and DNA in both left and right
breast; 36 control mothers had 81 samples. This study differs from
the previous study which investigated the association between
postnatal HIV acquisition at 6–28 weeks and cumulative cell-free
HIV exposure (i.e. the overall amount of cell-free viral particles
ingested by the infant during breastfeeding, upto infection or
equivalent age of control) [19]. The volume of milk ingested per
day was estimated by pattern of feeding and the probability of
transmission estimated per liter of breastmilk ingested. However,
that study did not access the influence of cell-associated virus
integrated in latent T cells on postnatal transmission. In contrast,
the current study presents the association between cell-free and
cell-associated shedding of HIV-1 virus in breastmilk and postnatal
HIV-1 transmission.
Quantification of HIV-1 Cell-free and Cell-associated Virus
Cell-free HIV-1 quantification on breastmilk samples was
performed as described previously [19]. Cell-associated HIV-1
quantification on whole breastmilk samples was performed using
the Generic HIV DNA Cell assay (Biocentric, Bandol, France).
Breastmilk samples were thawed at room temperature and vortex
mixed. A maximum of 1.5 ml (range 0.5–1.5 ml) of breastmilk was
aliquoted into a 2 ml microtube, centrifuged at 2000 g for 15 min
and the lactoserum-lipid layer was removed to a 1.5 ml microtube.
The lactoserum-lipid fraction was stored at 280uC. The
remaining breastmilk pellet was used in the HIV DNA real time
PCR (qPCR) assay. RNA was isolated from 500 mL of lactoserum
with use of the magnetic particle-based ASPS method (Abbott),
and HIV load was quantified using the Generic HIV Charge
Virale assay (Biocentric, Bandol, France) on the MJ MiniOpticon
quantitative PCR detection platform (Biorad), with a sensitivity of
375 copies per mL of lactoserum [26]. This method enabled
accurate assessment of cell-free viral load entrapped by lipids [27].
The Qiagen DNA Mini Kit was used to isolate total DNA from
the dry breastmilk pellet according to the manufacturer’s
instructions. Total DNA concentration was measured with the
Nanodrop instrument using 1 ml of sample. Samples with a DNA
concentration of ,50 ng/ml were tested neat. For samples with
a DNA concentration of .50 ng/ml an appropriate dilution of up
to 1:10 was performed. The total reaction volume was 50 ml with
a 20 ml sample input volume, according to manufacturer’s
instructions.
The human GAPDH housekeeping gene (Primer_F : 59-
AAGGTCGGAGTCAACGGATT-39; Primer_R R: 59-
CTCCTGGAAGATGGTGATGG-39) was quantified by real-
time PCR using SybrGreen to verify the integrity of the extracted
DNA, to determine the presence or absence of inhibitors/
contaminants, and to act as a reference gene for quantitative
analysis [28–30]. Quantifying the host gene GAPDH provided an
estimate of the number of cells per PCR, allowing expression of
the number of copies of HIV per 106 cells in our sample despite
not having a cell count.
HIV-1 Transmission through Breastfeeding
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Statistical Analysis
The analyses included transmitters and controls with both cell-
free and cell-associated results available from the same breastmilk
sample at 6 weeks and 6 months. When the 6 months results were
more than 4 weeks after transmission, the RNA result closest to the
transmission was used (RNA was quantified at multiple time
points) while the average between the two DNA results was
calculated, otherwise the result at 6 months was used. Breastmilk
HIV-1 RNA viral load levels below the lower detectable limit (375
copies/ml) were assigned a value at the midpoint between this and
zero (187.5 copies/ml) [31,32]. Breastmilk HIV-1 DNA samples
below the lower detectable limit were normalized for the amount
of cells used to isolate the DNA (based on the GAPDH
measurement which is different for each cell) [33]. No breastmilk
samples were excluded because of low cell counts as all samples
had DNA values above zero. Cell-free and cell-associated virus
levels were analyzed on a decimal logarithmic scale to base-10
[11,18]. Counts of DNA quantified per million cells were
converted to concentrations of DNA per milliliter by multiplying
by 0.086106 at 6 weeks and 0.056106 at 6 months breastmilk cells
per milliliter, as suggested in previous studies [11,34].
Chi-square test assessed differences in categorical variables
while Wilcoxon rank-sum test was used for non-parametric
analysis of continuous variables. Spearman rank correlation
estimated correlation between continuous variables. Cox re-
gression models, pooling multiple measurements from the left
and right breastmilk samples, assessed the association between
breastmilk cell-free and cell-associated virus levels and risk of
postnatal HIV-1 transmission. Observation time was taken from 6
weeks of age (last negative HIV PCR assay) to the estimated time
of HIV-1 infection or end of observation (6 months of age),
whichever came first. Multivariable models included maternal
antenatal CD4 cell count and plasma RNA [18], and were
stratified by time (6 weeks and 6 months) because there are more
infected cells in early than mature breastmilk [11]. The model
adjusting for both antenatal CD4 count and viral load represented
the best fit of the data using BIC and was thus retained as the final
model. Data were analysed using Stata Version 11.2 (2009
StataCorp, College Station, Texas, USA).
Results
A total of 166 HIV-1 RNA and DNA samples were included in
this analysis from 72 mothers (36 in each of transmitters and
controls); 81% predominantly breastfed (infants mainly received
breastmilk plus water or water-based drinks but no other milk or
food based fluid) for the first 6 months. 13.9% (5 of 36) of
transmitting mothers had RNA and DNA below lower detectable
limit in the last available breastmilk sample before transmission
occurred. Transmitting mothers were more likely to have lower
antenatal CD4 cell counts (p,0.001) and higher plasma viral load
(p,0.001) than controls (Table 1). The median time to trans-
mission in the cases was 85 (IQR 66–114) days (Figure 1).
Across all samples tested, cell-free virus was above detectable
limit in 76.5% (65/85) of breastmilk samples in the 36
transmitters and in 55.6% (44/81) in controls (p = 0.004); at 6
weeks and 6 months, prevalence was 79.1% and 73.8% in
transmitters and 60.9% and 50.0% in controls, respectively.
Overall, cell-associated virus was above detectable limit in
76.5% (65/85) of breastmilk samples in transmitters and in
45.7% (37/81) in controls (p,0.001); at 6 weeks and 6 months,
prevalence was 76.7% and 76.5% in transmitters and 46.3%
and 45.0% in controls, respectively. The detection levels of cell-
free and cell-associated virus were similar in right and left
breast; 43.8% and 56.9% (p= 0.092), respectively, for cell-free
virus and 67.5% and 55.8% (p= 0.122), respectively, for cell-
associated virus.
HIV-1 RNA and DNA Loads in Breastmilk
Cell-free virus levels ranged from below detection to a maximum
of 1,590,000 copies per ml at 6 weeks and 6 months; cell-
associated virus levels ranged from below detection to a maximum
of 137,441 copies per ml. Median log10 cell-free values per
milliliter were higher than cell-associated values per milliliter (2.8
vs. 2.3 at 6 weeks; p,0.001 and 2.7 vs. 2.4 at 6 months; p,0.001,
respectively). Transmitting mothers had significantly higher log10
values of cell-free (median: 3.6 vs. 2.7; p,0.001 at 6 weeks and 3.5
vs. 2.3; p,0.001 at 6 months) and cell-associated per milliliter
(median: 2.7 vs. 2.1; p,0.001 at 6 weeks and 2.6 vs. 2.2; p,0.001
at 6 months) values than controls (Figure 2).
The breastmilk cell-free and cell-associated levels were similar
between breasts at both time points in the first 6 months
postpartum (Figure 3). Overall, cell-free virus per milliliter and
cell-associated virus levels per million cells were significantly
positively correlated (r=0.34, p,0.001); these correlation was
maintained at 6 weeks (r=0.37, p,0.001) and at 6 months
(r=0.32, p,0.001). Similarly, a positive correlation was obtained
between cell-free virus per milliliter and cell-associated virus per
milliliter (r=0.33, p,0.001); these correlation was also maintained
at 6 weeks (r=0.38, p,0.001) and at 6 months (r=0.32,
p,0.001). Breastmilk cell-free virus levels were positively corre-
lated with antenatal maternal plasma viral load (overall RNA:
r=0.46, p,0.001; at 6 weeks r=0.46, p,0.001 and at 6 months
r=0.47, p,0.001) and negatively with maternal CD4 cell count
(RNA: r=20.44, p,0.001; at 6 weeks r=20.43, p,0.001 and at
6 months r=20.46, p,0.001). Similarly, breastmilk cell-associat-
ed virus levels per milliliter were positively correlated with
antenatal maternal plasma viral load (overall DNA: r=0.30,
p,0.001; at 6 weeks r=0.35, p,0.001 and at 6 months r=0.26,
p,0.001) and negatively with maternal CD4 cell count (DNA:
r=20.33, p,0.001; at 6 weeks r=20.37, p,0.001 and at 6
months r=20.29, p,0.001). Log10 cell-free and cell-associated
virus levels in breastmilk were significantly higher in mothers with
antenatal CD4 count below 500 compared to those with at least
500 cells per mm3 (median: 3.2 vs. 2.7, p,0.001 for cell-free and
3.7 vs. 3.3, p,0.001 for cell-associated virus levels).
Correlation with HIV-1 Transmission
In univariate Cox analysis, each 10-fold increase in the average
(between 6 weeks and 6 months) cell-free and cell-associated levels
was associated with a significant 2- and a 4-fold increase in
breastmilk transmission (HR 2.18 (95% confidence interval (CI)
1.66–2.87) and 4.18 (95% CI 2.24–7.79) respectively). Multi-
variably, adjusting for antenatal CD4 count and maternal plasma
viral load, each 10-fold increase in cell-free or cell-associated levels
was significantly associated with an approximate 2-fold increase in
breastmilk transmission [adjusted hazard ratio (aHR) 1.96 (95%
confidence interval (CI), 1.17–1.96) and 2.57 (95% CI 1.26–5.28)
respectively].
A Cox regression model was fitted for the HIV-1 RNA and
DNA breastmilk samples collected at both 6 weeks and 6 months
to control for potential variation in levels over time [11]. The
trend suggested that at 6 weeks, HIV-1 DNA levels in breastmilk
were more important for HIV-1 transmission than RNA (aHR
1.98 vs. 1.16, both P.0.05). Conversely, at 6 months, RNA levels
were more important than DNA (aHR 1.99 vs. 1.21, both
p.0.05). However, statistical power was lost, possibly due to
collinearity between the 6 weeks and 6 months HIV-1 RNA and
HIV-1 Transmission through Breastfeeding
PLOS ONE | www.plosone.org 3 December 2012 | Volume 7 | Issue 12 | e51493
DNA results. Therefore, we stratified the analysis by timing of the
sample at 6 weeks and 6 months.
In univariate analyses, at 6 weeks, each 10-fold increase in
breastmilk cell-free or cell-associated levels per ml was associated
with significantly increased hazard of postnatal HIV-1 trans-
mission [HR 1.63 and 3.38, respectively] (Table 2). Multivariably,
DNA was more important for HIV-1 transmission than RNA
[aHR 2.47 vs. 1.52].
At 6 months, each 10-fold increase in breastmilk cell-free or cell-
associated levels per ml was univariately associated with an almost
3-fold significantly increased hazard of postnatal HIV-1 trans-
mission (Table 2). However, multivariably, the association was
stronger for RNA than DNA levels [aHR 2.53 vs. 1.73].
Figure 1. Kaplan-Meier curve showing transmission probabilities after 6 weeks of age.
doi:10.1371/journal.pone.0051493.g001
Table 1. Baseline characteristics of Infants and HIV-positive mothers transmitting HIV-1 through breastmilk and their controls.
Infant or Maternal characteristic Cases (n=36) Controls (n=36) P
Age (years), median (IQR) 25.5 (22.2–28.2) 27.3 (21.1–29.9) 0.502
Antenatal CD4 count cells/mL, median (IQR) 337 (198–540) 524 (369–697) ,0.001
Antenatal viral load log10 copies/mL, median (IQR) 4.5 (4.2–5.0) 4.0 (3.5–4.6) ,0.001
Water source
Non-piped 13 (36.1) 11 (30.6) 0.714
Piped 23 (63.9) 25 (69.4)
Enrollment clinic
Rural 16 (44.4) 14 (38.9) 0.764
Peri-urban 11 (30.6) 12 (33.3)
Urban 9 (25.0) 10 (27.8)
Maternal education
None 2 (5.6) 5 (13.9)
Some primary 12 (33.3) 14 (38.9)
Secondary and above 22 (61.1) 17 (47.2) 0.226
Birth weight (grams), median (IQR) 3200 (2800–3400) 3100 (2800–3500) 0.572
Birth head circumference, median (IQR) 34.8 (33.5–36.4) 35.0 (33.6–36.0) 0.828
Chi-square test assessed differences in categorical variables while Wilcoxon rank-sum test was used for non-parametric analysis of continuous variables.
Abbreviations: Cases, HIV-1 infected postnatal transmitters; Controls, non-transmitting HIV-1 infected mothers.
doi:10.1371/journal.pone.0051493.t001
HIV-1 Transmission through Breastfeeding
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Discussion
We examined the prevalence of detectable RNA and DNA and
levels of cell-free and cell-associated HIV-1 and associated risk of
postnatal transmission at 6 weeks and 6 months in a case-control
study nested in a cohort of HIV-infected mothers in KwaZulu-
Natal. We showed higher median levels of cell-free than cell-
associated HIV-1 virus per milliliter in breastmilk at 6 weeks and 6
months, with similar levels between breasts. Both cell-free and cell-
associated virus levels in breastmilk were significantly associated
with HIV-1 transmission, with a suggestion that cell-associated
virus levels per milliliter may be more strongly associated with
transmission than cell-free virus levels per milliliter at 6 weeks and
less so at 6 months.
The prevalence of detectable HIV-1 cell-free virus in all
breastmilk samples was comparable to that in previous African
Figure 2. Distribution of observed log10 cell-free and cell-associated values by age of infant.
doi:10.1371/journal.pone.0051493.g002
Figure 3. Distribution of log10 cell-free and cell-associated values (per ml) by breast and infant age.
doi:10.1371/journal.pone.0051493.g003
HIV-1 Transmission through Breastfeeding
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studies [12,18,31] as was that of cell-associated virus [35,36].
Among the HIV-1 transmitting mothers, the prevalence of cell-
associated virus in our study was similar to a Ugandan study at 6
weeks postpartum (77% vs. 80%, respectively) [37]. Our study
showed no statistically significant difference between breasts in the
levels of HIV-1 cell-free and cell-associated virus, and confirms
a strong correlation of HIV-1 cell-free and cell-associated virus in
breastmilk [19,38]. This would suggest that breastmilk samples can
be collected from either breast in future studies investigating HIV-
1 shedding in breastmilk. Our study also confirms a positive
correlation between breastmilk HIV-1 RNA and DNA and
maternal antenatal plasma viral load and a negative correlation
with maternal antenatal CD4 cell count [11,12].
Previous studies have suggested that cell-associated virus levels
in breastmilk decline over time [35,36] whereas cell-free virus
levels increases [39]. Overall, we show a marginally declining
trend in both cell-free and cell-associated virus levels in breastmilk
starting at 6 weeks postpartum [12,36], although mothers
transmitting HIV-1 had significantly higher levels of cell-free
and cell-associated virus over time, as seen elsewhere [11].
Breastmilk cell-free and cell-associated levels (per ml) were
significantly associated with postnatal HIV-1 transmission both
univariately and multivariately. The overall adjusted model
showed a 2-fold increased risk of HIV-1 transmission through
breastmilk with each 10-fold increase in RNA or DNA levels as
previously reported [12,18,19]. This is in line with results from
a study in Nairobi which reported a significant association between
the infected breastmilk cells and the risk of HIV-1 transmission
during or after delivery [11]. Unlike our study, almost two-thirds
of the first breastmilk samples in that study were collected less than
10 days after birth. Additionally, we show that at 6 weeks, DNA
was more strongly associated with postnatal HIV-1 transmission
than RNA while at 6 months, RNA was more strongly associated
than DNA; few studies have compared RNA and DNA levels and
the risk of postnatal HIV-1 transmission in the same population in
early postpartum. Our results suggest that breastmilk cell-
associated levels decrease earlier than noted in previous studies
investigating HIV-1 transmission 9 months post-delivery [18,40].
Future studies investigating cell-associated virus levels - especially
distinguishing latently non-producing infected cells from activated
producing cells - and HIV-1 transmission during lactation should
be designed to focus on early life.
The current prevention of mother-to-child transmission
(PMTCT) guidelines in South Africa recommend zidovudine
(AZT) from 14 weeks of pregnancy, sdNVP and 3-hourly AZT
intrapartum, and a single dose of tenofovir and emtracitabine
postpartum, for women not eligible for lifelong ART. Their infants
receive daily NVP for 6 weeks and then for up to one year during
breastfeeding. Women with CD4 below 350 are eligible for
lifelong ART and their infants get 6 weeks daily NVP only [41].
However, during the study period, only sdNVP was available for
HIV infected women during labour/delivery and for their
newborns immediately postnatally [42]. Previous studies suggest
that sdNVP may reduce early postnatal HIV-1 transmission [43],
as the drug has a long half-life and can be found in maternal
plasma and breastmilk up to 3 weeks postpartum [44], and may
reduce cell-free virus levels in the early postpartum period [45].
NVP also has a good penetration in anatomic compartments
leading to reduced levels of HIV-1 plasma viral loads [46]. In our
study, the estimated risk of HIV-1 transmission associated with
RNA relate to samples taken at 6 weeks after perinatal sdNVP
exposure, while the 6 months samples are in the absence of ART,
which may partly explain the higher risk of transmission associated
with RNA at 6 months. In our primary study, without ART, the
HIV-1 transmission rate was 14.1% at 6 weeks and 19.5% at 6
months in exclusively breastfed infants [23]. In the recent clinical
trials, where HIV-infected pregnant women took triple-ARV
regimen from about 28 weeks in pregnancy (or after delivery) to 6
months postpartum, HIV transmission ranged from 3.3%–4.2% at
6 weeks and from 1.1%–8.2% at 6 months [47–51]. These findings
suggest that giving breastfeeding women a triple-ARV regimen is
safe and feasible to reduce MTCT in resource-limited settings.
However, there are suggestions that the effect of ART is
different on cell-free and cell-associated virus in breastmilk [20].
Results from two separate clinical trials comparing HIV-1 cell-free
and cell-associated virus in breastmilk suggest that triple-ARV
regimen during pregnancy or after delivery suppressed cell-free
but not cell-associated HIV-1 loads in breastmilk [33,52]. The
undetectable HIV-1 RNA in both plasma and breastmilk has been
interpreted as reflecting the cessation of viral replication within
maternal lymphoid tissues [53] and in the mammary gland [54].
As cell-associated HIV-1 virus in breastmilk is associated with
HIV-1 transmission through breastfeeding [11,18], their detection
in breastmilk of untreated as well as those receiving antiretroviral
therapy might be responsible for a residual breastmilk transmission
with maternal ART.
Opportunistic infections such as congenital cytomegalovirus
during pregnancy or delivery, mastitis and breast abscess have
Table 2. Risk factors for HIV-1 transmission through breastfeeding.
First sample taken at 6 weeks Second sample close to ETT (or at 6 months)
Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis
Variable HR (95% CI) P aHR (95% CI) P HR (95% CI) P aHR (95% CI) P
RNA load (for each additional
log10 copies/ml)
1.63 (1.33–1.98) ,0.001 1.52 (1.17–1.96) 0.002 2.65 (1.87–3.76) ,0.001 2.53 (1.64–3.92) ,0.001
DNA load (for each additional
log10 copies/ml)
3.38 (1.92–5.93) ,0.001 2.47 (1.33–4.59) 0.004 2.72 (1.55–4.77) ,0.001 1.73 (0.94–3.19) 0.077
Antenatal CD4 count (for each
additional 100 cell/mL)
0.91 (0.79–1.04) 0.173 1.09 (0.97–1.22) 0.147 0.91 (0.79–1.04) 0.173 1.09 (0.96–1.24) 0.200
Antenatal viral load (for each
additional log10 copies/ml)
2.11 (1.30–3.43) 0.002 1.39 (0.79–2.45) 0.252 2.11 (1.30–3.43) 0.002 1.09 (0.60–1.97) 0.777
Estimated by Cox regression with adjustment on the other factors reported in the table.
Abbreviations: HR, hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio; ETT estimated time of transmission.
doi:10.1371/journal.pone.0051493.t002
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been found to be associated with the risk of HIV transmission
intrapartum or postpartum [16,55]. However, in our study, serious
breast health problems were rare and there were no significant
differences between HIV-infected and uninfected women [56].
The strengths of our study include the large number of
breastmilk samples in the first six months postpartum and the
concurrent measurement of cell-free and cell-associated virus in
the right and left breasts. These findings, from a study conducted
before ART was available in public health programmes in South
Africa, increase understanding of the mechanisms of postnatal
transmission, important for optimizing delivery of interventions in
the current period.
In summary, cell-associated virus load in breastmilk is a stronger
predictor of the risk of early postnatal HIV-1 infection than cell-
free virus loads, independent of antenatal CD4 cell count and
plasma viral loads. In contrast, cell-free virus load is a stronger
predictor of later postnatal HIV-1 transmission. In contemporary
breastfeeding populations with access to antiretroviral prophylaxis
and ART, the residual HIV-1 transmission risk especially in the
early postpartum period is partly explained by the persistence of
cell-associated virus in breastmilk, and highlights a potential
challenge of resource-limited settings to achieve the current
UNAIDS goal for 2015 of eliminating new vertical transmission
[57]. More studies are therefore needed to further knowledge on
the mechanism of HIV-1 transmission during lactation and to help
develop more effective drugs for use in resource-limited popula-
tions where avoidance of breastfeeding is almost impossible.
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